Table 1.
Survival analysis of prognostic predictors in pancreatic ductal adenocarcinoma.
| AS events |
E/N (Low) |
MST (Low) |
E/N (High) |
MST (High) |
UniCox HR (95% CI, H vs. L) |
Log-Rank P | MultiCox HR (95% CI, H vs. L) | Adjusted P |
|---|---|---|---|---|---|---|---|---|
| OS | ||||||||
| AA | 25/60 | 702 | 39/60 | 518 | 2.15 (1.30–3.56) | 0.002 | 2.03 (1.15–3.59) | 0.015 |
| AD | 25/60 | 738 | 39/60 | 486 | 2.30 (1.38–3.81) | 0.001 | 3.46 (1.81–6.62) | < 0.001 |
| AP | 24/60 | 702 | 40/60 | 481 | 2.35 (1.41–3.91) | 0.001 | 2.30 (1.23–4.31) | 0.010 |
| AT | 24/60 | 738 | 40/60 | 486 | 2.53 (1.51–4.23) | < 0.001 | 2.68 (1.48–4.85) | 0.001 |
| ES | 22/60 | 1502 | 42/60 | 486 | 2.71 (1.61–4.58) | < 0.001 | 3.39 (1.86–6.16) | < 0.001 |
| ME | 27/60 | 666 | 37/60 | 498 | 1.58 (0.95–2.63) | 0.073 | 1.86 (1.06–3.26) | 0.031 |
| RI | 26/60 | 702 | 38/60 | 486 | 2.06 (1.24–3.40) | 0.004 | 2.04 (1.12–3.72) | 0.019 |
| All AS | 25/60 | 702 | 39/60 | 476 | 2.44 (1.46–4.08) | < 0.001 | 2.80 (1.38–5.69) | 0.004 |
| RFS | ||||||||
| AA | 15/60 | 1210 | 35/60 | 390 | 3.76 (2.03–6.95) | < 0.001 | 5.22 (2.42–11.26) | < 0.001 |
| AD | 12/60 | 1600 | 38/60 | 439 | 4.28 (2.18–8.40) | < 0.001 | 3.41 (1.69–6.89) | 0.001 |
| AP | 18/59 | 831 | 32/61 | 513 | 1.99 (1.11–3.55) | 0.024 | 2.29 (1.21–4.36) | 0.011 |
| AT | 18/59 | 1309 | 32/61 | 486 | 2.58 (1.43–4.66) | 0.002 | 2.74 (1.38–5.42) | 0.004 |
| ES | 16/60 | 872 | 34/60 | 439 | 2.60 (1.43–4.73) | 0.001 | 2.36 (1.22–4.59) | 0.011 |
| ME | 23/59 | 593 | 27/61 | 542 | 1.34 (0.77–2.35) | 0.419 | 1.87 (0.97–3.58) | 0.060 |
| RI | 18/60 | 872 | 32/60 | 443 | 2.30 (1.28–4.11) | 0.004 | 3.00 (1.55–5.81) | 0.001 |
| All AS | 13/60 | 1210 | 37/60 | 375 | 4.93 (2.60–9.36) | < 0.001 | 11.20 (4.38–28.62) | < 0.001 |
Multivariate Cox proportional hazards regression model was adjusted by age, gender, tumor stage, residual tumor status, targeted molecular therapy, and radiation therapy.